市場調査レポート

世界の足白癬(水虫)市場

Tinea Pedis (Athlete's Foot)

発行 Global Industry Analysts, Inc. 商品コード 134328
出版日 ページ情報 英文 269 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界の足白癬(水虫)市場 Tinea Pedis (Athlete's Foot)
出版日: 2010年08月01日 ページ情報: 英文 269 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の足白癬(水虫)市場について調査し、足白癬(水虫)の概要と治療法、研究開発動向、業界活動、地域別動向とともに、参入する企業のプロファイルと競合状況などをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 米国市場レポート

  • 業界概要
    • 前兆
    • 現在および将来分析
    • 市場動向
    • 主な統計
  • 足白癬(水虫)の概要
    • イントロダクション
    • 種類
    • 接触伝染性性質
    • 足の発疹の原因
    • 症状
    • 診断
    • 治療
    • 治療プロセス
    • 合併症
    • 結論
  • 入手可能な薬剤
    • 経口局所投与薬剤
    • 治療法レビュー
  • 研究開発
    • 治験
    • その他のイニシアティブ
  • 近年の業界活動
  • 主要企業

第3章 競合状況

  • 企業プロファイル:43社(事業部・子会社含め50社)
    • 米国
    • カナダ
    • 日本
    • 欧州
    • アジア太平洋地域(日本を除く)
    • ラテンアメリカ
    • アフリカ
    • 中東
目次
Product Code: MCP-6540

Abstract

This report analyzes the US market for Tinea Pedis (Athlete' s Foot) in US$ Million. Annual estimates and forecasts are provided for the period of 2006 through 2015. The report profiles 43 companies including many key and niche players such as Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Kaken Pharmaceutical Co., Ltd., Merck & Co., Inc., Nitric BioTherapeutics, Inc., Novartis AG, Sanofi-Aventis, Stiefel Laboratories, Inc., and Topica Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW

  • A Curtain Raiser
  • Distribution and Prevalence of Tinea Pedis
  • Table 1: Global Tinea Pedis (Athlete' s Foot) Market (2009E): Percentage Breakdown of Global Prevalence of Fungal Infections of the Skin by Country - France, Germany, Italy, UK, US, and Japan (includes corresponding Graph/Chart)
  • Statistical Insights
  • Foot Facts & Figures
  • Current and Future Analysis
  • Table 2: US Recent Past, Current and Future Analysis for Tinea Pedis (Athlete' s Foot) with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Market Dynamics
  • Introduction of Novel Formulations Spurs Demand
  • Aging Population Revs up Anti-Fungal Market
  • Table 3: US Population by Age Group: 2010E (includes corresponding Graph/Chart)
  • Market Challenges
  • Time Consuming Clinical Trials Stall Growth
  • Table 4: Tinea Pedis (Athlete' s Foot) Products by Different Phases of Development (2009) - Marketed Products, Discontinued Projects, Phase I Trials, Phase II Trials, and Under Development (includes corresponding Graph/Chart)
  • Low Levels of Patient Compliance Reduces Revenue Potential
  • Lack of Public Awareness Prevents Market Growth
  • Key Statistical Findings
  • Table 5: Global Dermatology Market (2009) - Number of Marketed and Pipeline Products in Phase I, II and III Globally Available By Indication - Skin Infections, Skin Disorders, Acne, Skincare, Wounds, and Tinea Pedis (includes corresponding Graph/Chart)
  • Table 6: Global Tinea Pedis (Athlete' s Foot) Market (2009): Number of Available Marketed Products for Tinea Pedis (Athlete' s Foot) by Company - Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Kobayashi Pharmaceutical Co., Ltd., Novartis AG, and Taisho Pharmaceutical Co., Ltd. (includes corresponding Graph/Chart)

2. AN OVERVIEW OF TINEA PEDIS (ATHLETE' S FOOT)

  • An Introduction
  • Types
  • Moccasin Tinea Pedis
  • Interdigital Tinea Pedis
  • Inflammatory or Bullous Tinea Pedis
  • Contagious Nature of the Disease
  • Person to Person
  • Transmission to Other Body Parts
  • Object to Person
  • Animal to Person
  • Causes of Foot Rashes
  • Symptoms
  • Diagnosis
  • Importance of Timely Diagnosis
  • Preventive Measures
  • At Home
  • At Public Places
  • Personal Preventive Measures
  • Treatments
  • Traditional Treatment
  • Topical Medications
  • Oral Medications
  • Identifying Optimal Formulation
  • Alternative Treatment
  • Treatment Process
  • Complications
  • Conclusion

3. SELECT DRUGS AVAILABLE FOR TINEA PEDIS

  • Oral and Topical Agents for Tinea Pedis
  • Select Anti-Fungal OTC and Prescription Drugs Available by the Mechanism of Action
  • Review of Select Treatments
  • Ertaczo (Sertaconazole Nitrate)
  • Lamisil® (Terbinafine)
  • Lotrimin Ultra (Butenafine)
  • Naftin (Naftifine Hydrochloride)
  • Oxistat (Oxiconazole Nitrate)
  • Penlac®

4. RESEARCH AND DEVELOPMENT

  • Clinical Trials
  • Nitric BioTherapeutics Starts Phase II Onychomycosis Study
  • Topica Pharmaceuticals Begins Phase 2 Clinical Trial of Luliconazole
  • Other Research & Development Initiatives

5. RECENT INDUSTRY ACTIVITY

  • Sanofi Acquires Chattem
  • Topica Pharmaceuticals Gets FDA Approval for Luliconazole IND (US)
  • Nitric BioTherapeutics Purchase New Technology Platform and Advanced Clinical Programs
  • Ranbaxy Laboratories Introduces Lulifin (India)
  • Schering-Plough Launches Tinactin Chill
  • Paddock Laboratories Receives FDA Approval for Ciclopirox Gel
  • Peng Lai Jin Chuang Pharmaceutical Receives Production Approval from SFDA (China)

6. FOCUS ON KEY PLAYERS

  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Johnson & Johnson (US)
  • Kaken Pharmaceutical Co., Ltd. (Japan)
  • Merck & Co., Inc. (US)
  • Nitric BioTherapeutics, Inc. (US)
  • Novartis AG (Switzerland)
  • Sanofi-Aventis (France)
  • Stiefel Laboratories, Inc. (US)
  • Topica Pharmaceuticals, Inc. (US)

III. COMPETITIVE LANDSCAPE

Back to Top